The Latest Cardiac and Vascular News
MARLBOROUGH, Mass., April 27, 2022 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.026 billion during the first quarter of 2022, growing 10.0 percent on a reported basis, 12.6 percent on an operational1 basis and 9.7 percent on an organic2 basis, all compared to […]
MARLBOROUGH, Mass., Feb. 28, 2022 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced positive results from a new analysis assessing real-world outcomes with the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. Presented during a late-breaking trial session at the Cardiovascular Research Technologies […]
MARLBOROUGH, Mass., Feb. 15, 2022 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Baylis Medical Company Inc., a company that offers advanced transseptal access solutions as well as guidewires, sheaths and dilators used to support catheter-based left-heart procedures. “The […]
Trial studying communication between cardiac rhythm management devices aims to expand treatment options for patients who require an ICD MARLBOROUGH, Mass., Dec. 2, 2021 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) has initiated the MODULAR ATP clinical trial to evaluate the safety, performance […]
MARLBOROUGH, Mass., Oct. 27, 2021 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.932 billion during the third quarter of 2021, growing 10.3 percent on a reported basis, 9.7 percent on an operational1 basis and 10.6 percent on an organic2 basis, all compared […]
Late-breaking data demonstrate superior rates of primary patency and statistically significant sustained clinical improvement LAS VEGAS and MARLBOROUGH, Mass., Oct. 6, 2021 /PRNewswire/ — Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System (Eluvia stent) during a late-breaking […]
Analysis found no intracerebral hemorrhages, low major bleeding rates; registry represents largest data set in interventional treatment of pulmonary embolism LAS VEGAS and MARLBOROUGH, Mass., Oct. 5, 2021 /PRNewswire/ — Today, Boston Scientific (NYSE: BSX) announced positive results for the EkoSonic™ Endovascular System (EKOS system) during […]
Baylis Medical Technologies to increase investment in radiology and neurosurgery business in Canada MISSISSAUGA, Ont. (October 6, 2021) – Baylis Medical Company Inc. is pleased to announce it has reached an agreement to sell its cardiology business to Boston Scientific […]
Two-year data demonstrate continued high rates of primary patency including in patients with complex lesions LAS VEGAS and MARLBOROUGH, Mass., Oct. 5, 2021 /PRNewswire/ — Today, Boston Scientific (NYSE: BSX) announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during a late-breaking clinical trial presentation at […]
Company to add mechanical thrombectomy platform to peripheral interventions portfolio MARLBOROUGH, Mass., Sept. 21, 2021 /PRNewswire/ — Today, Boston Scientific Corporation (NYSE: BSX) announced an agreement to acquire Devoro Medical, Inc., developer of the WOLF Thrombectomy® Platform. The innovative non-console and lytic-free WOLF technology targets […]
